Five Stocks Earning Fresh Research Analyst Attention – Costco, Roche, Lam Research, Spruce Power, and IDT Analyzed

When research analysts dive deep into market data, certain stocks consistently rise to the surface as worthy of investor scrutiny. Late February 2026 brought fresh analysis from Zacks’ team of market specialists, who zeroed in on five companies spanning retail, pharmaceuticals, semiconductors, clean energy, and communications. This comprehensive research analyst review reveals winners outpacing their sectors and challengers navigating significant headwinds.

The Research Analyst Consensus: Winners and Laggards Over Six Months

The research analysts tracking these five stocks identified a clear performance split. Costco gained 5.2% as its industry surged 12.5%, suggesting the retail giant underperformed relative peers. Meanwhile, Roche’s shares jumped 49.5% against a Large Cap Pharmaceuticals sector gain of just 27.8%, positioning the Swiss pharma company as a notable outperformer. Lam Research dominated its peers with a 140.9% surge when the Electronics-Semiconductors space delivered 25.5%, marking the strongest relative performer on this research analyst watch list. Spruce Power’s 195.8% jump outpaced its Electronics-Miscellaneous Products peers at 35.3%, while IDT disappointed with a -21% decline as its Diversified Communication Services industry gained 5.2%.

Costco: Consumer Resilience Masks Relative Sector Softness

What sets Costco apart, according to the research analyst team, is its operational fortress defending it from market turbulence. The Kirkland Signature private label brand continues driving margin expansion, while membership renewal rates and growing member bases fuel recurring revenue streams. Robust e-commerce momentum and expanding digital fulfillment services have amplified the company’s omnichannel footprint, driving consistent store traffic.

Management’s proactive supply-chain diversification and sourcing efficiency are absorbing tariff and input-cost pressures without sacrificing the company’s hard-won price leadership position. Strong cash generation, balance-sheet flexibility, and a proven track record executing through economic cycles position Costco to maintain earnings momentum despite underperforming its peer group on a six-month basis.

Roche’s Pharmaceutical Pivot: Stars Rising Amid Legacy Drug Fade

Research analysts tracking Roche see a company navigating a critical inflection point. The multiple sclerosis drug Ocrevus and ophthalmology treatment Vabysmo are driving momentum, while hemophilia therapy Hemlibra and breast cancer drug Phesgo add growth tailwinds. Yet legacy franchises—Avastin, Herceptin, MabThera, and Actemra—face biosimilar competition that continues eroding revenues.

Roche is deliberately diversifying through strategic acquisitions and partnerships to offset these structural headwinds. However, pipeline setbacks have weighed on stock momentum. An additional drag came from unfavorable foreign-exchange movements in the 2025 results period, as U.S. dollar weakness pressured international sales conversion. Despite these challenges, research analysts note that management’s ability to refresh the portfolio partially explains why Roche significantly outperformed its pharmaceutical peer group.

Lam Research: Riding the Semiconductor Supercycle – With Trade War Shadows

Among the five stocks, research analysts see Lam Research as perhaps best positioned for growth. The company’s dominance in 3D DRAM and advanced packaging technologies aligns perfectly with industry trends. Growing etch and deposition intensity, driven by advancing 3D chip architectures, supports demand for its wafer fab equipment (WFE).

A rebound in the System business is in sight due to recovering memory spending, while strategic R&D investments position Lam to capitalize on expanding global WFE capital budgets. Foundry/logic, DRAM, and NAND equipment investments are all trending higher year-over-year. Solid demand for high-bandwidth memory chips represents a meaningful upside catalyst.

Yet research analysts monitoring the company flag a critical headwind: escalating trade and tariff tensions between the U.S. and China threaten near-term growth assumptions. Additionally, global spending on mature semiconductor nodes is likely to remain sluggish, limiting some demand avenues.

Spruce Power: Scalable Solar Model Meets Refinancing Reality

This microcap company caught research analyst attention for its capital-light business model. With 85,000 residential solar systems generating stable, long-term contracted revenues, Spruce delivered $30.7 million in Q3 2025 revenue (44% year-over-year growth) and $26.2 million in operating EBITDA. The company’s SREC monetization strategy adds high-margin incremental growth, including a $10 million hedged transaction extending through 2029.

Scalability is built into the model—Spruce avoids expensive installations by leveraging acquisitions and its proprietary Spruce PRO platform. Recent cost-reduction initiatives target $20 million in annual savings. A disciplined M&A strategy has added 67,000+ systems since 2018, yet research analysts express caution about a looming refinancing event. A $184 million debt facility maturing in April 2026 creates going-concern questions. High leverage and thin equity cushioning limit financial flexibility, while legal liabilities and customer concentration add further risk layers. At 4.12X EV/sales, however, valuation offers modest downside protection.

IDT: The Transformation Story – High-Margin Growth Ignites

Perhaps the most complex story on this research analyst roster is IDT, a microcap facing multiple pressures. Remittance-related working capital volatility, advertising softness at its NRS division, fee-rate compression, churn, capital intensity, regulatory uncertainty, and legacy business erosion all present headwinds. Yet research analysts tracking the company identify a meaningful transformation unfolding.

IDT’s revenue mix is deliberately shifting toward higher-margin growth engines. NRS is scaling a recurring, payments-led retail model delivering 22% revenue growth and 35% operating income expansion. BOSS Money’s digital channel (84% of transactions) is driving 160 basis points of margin expansion alongside 97% operating income growth, even as incremental fee pressure persists. Meanwhile, net2phone is leveraging artificial intelligence and bundled vertical solutions to expand ARPU and profitability. Legacy Communications remains a steady cash generator funding growth initiatives.

While this company’s market capitalization sits at just $1.23 million, research analysts see potential upside if the higher-margin business mix continues scaling and consolidated profitability improves. Valuation dynamics suggest limited downside risk and meaningful multiple-expansion potential.

The Bottom Line: What Research Analysts Are Watching Next

Zacks’ team of market specialists identified these five stocks because they represent different inflection points and challenges. Costco embodies stable consumer-defensive positioning, Roche is managing a critical pharmaceutical transition, Lam Research captures semiconductor-cycle upside with trade risks, Spruce Power scales renewables while facing refinancing tests, and IDT demonstrates margin improvement despite structural headwinds. For investors seeking fresh perspectives from research analysts who dig deep into company fundamentals and market positioning, these five stocks merit continued observation.